Technische Universität Berlin



# International Innovations to Improve the Quality and Value of Health Care: The German case


### Reinhard Busse, Prof. Dr. med. MPH FFPH

Dept. Health Care Management, Berlin University of Technology (WHO Collaborating Centre for Health Systems Research and Management), Charité – University Medicine Berlin & European Observatory on Health Systems and Policies










### Population

### **Providers**






# I will focus on three particular innovative examples:


- Quality measurement/ management in hospitals (-> 3 approaches) 2001
- 2. Disease Management Programs 2002
- 3. Evaluating cost-effectiveness ("value") of drugs 2008

(while I will "forget" other approaches such as minimum volumes for certain procedures, hospital quality reports, mandatory quality management systems ...)

### **Federal Office for Quality Assurance (BQS)** since 2001 mandatory for all ca. 1,700 hospitals, 169 indicators, 2.8 million cases (17%), with feedback and "structured dialogue"



### BQS - Benchmarking with all hospitals



Presentation at AcademyHealth Annual Research Meeting, June 2006.




### P4R

- Hospitals get €0.58 (\$ 0.9) per documented case
- If reported cases are <80% of respective reimbursed cases, payment is cut by €150 (\$ 235) per case up to 100%</li>
- If documentation is handed in late, hospital is fined €6,000 (\$ 9,400)

### Community acquired Pneumonia Blood gas analysis within 8 hours Hospital results in Hamburg 2005


The only non-surgical/ non-invasive indication included

% of patients who get the necessary blood gas analysis, objective: 100% each column represents a Hamburg hospital




### Hip Replacement Antibiotic Prophylaxis

% of patients who get the necessary prophylaxis, objective: > 95% each column represents a Hamburg hospital Hamburg data 2003 - 2005



Presentation at AcademyHealth Annual Research Meeting, June 2006.


#### Antibiotic Prophylaxis and Wound Infection in Hip-Replacement 2001 – 2005 Hamburg Hospitals - 3,500 cases per year



Source: Christof Veit, "The Structured Dialog: National Quality Benchmarking in Germany," Presentation at AcademyHealth Annual Research Meeting, June 2006.


#### Antibiotic Prophylaxis in Hysterectomies 2004–2005 152,000 cases, 97% completeness of data, results by state

Diagrams show percentage of patients receiving prophylaxis per state. Objective: >= 90%



Source: Christof Veit, "The Structured Dialog: National Quality Benchmarking in Germany," Presentation at AcademyHealth Annual Research Meeting, June 2006.

### National Results: Achievement of Quality Objectives in 2005



Source: Christof Veit, "The Structured Dialog: National Quality Benchmarking in Germany," Presentation at AcademyHealth Annual Research Meeting, June 2006.

Tabelle A: Vom Gemeinsamen Bundesausschuss als uneingeschränkt zur Veröffentlichung geeignet bewertete BQS-Qualitätsindikatoren

T	T CBL	D	Providence des Orabientes south	Kanana ki ID			avt nh	2001				
Leistungsbereich	LfdNr	Bezeichnung des Qualitätsindikators	Bezeichnung der Qualitätskennzahl	Kennzahl ID		Next phase:						
Cholezystektomie	2	Präoperative Diagnostik bei extrahepatischer Cholestase	Präoperative Diagnostik bei extrahepatischer Cholestase	2006/12n1-CH	IOL/44783	reporting of						
	3	Erhebung eines histolo- gischen Befundes	Erhebung eines histologischen Befundes	2006/12n1-CH	IOL/44800		report	ting o				
	7	Reinterventionsrate	Reinterventionsrate	2006/12n1-CH	IOL/44927							
Geburtshilfe	3	E-E-Zeit bei Notfallkaiser- schnitt	E-E-Zeit bei Notfallkaiserschnitt	2006/16n1-GE	BH/68383	indicator						
	4	Anwesenheit eines Pädiaters bei Frühgeborenen	Anwesenheit eines Pädiaters bei Frühgeborenen	2006/16n1-GE	BH/737	indicator						
	10	Antenatale Kortikosteroidtherapie	Antenatale Kortikosteroidtherapie: bei Geburten mit einem Schwangerschaftsalter von 24+0 bis unter 34+0 Wochen unter Aus- schluss von Totgeburten und mit einem präpartalen stationären Auf- enthalt von mindestens zwei Kalendertagen	2006/16n1-GE	BH/49523	n		atory				
Gynäkologische Operationen	7	Antibiotikaprophylaxe bei Hysterektomie	Antibiotikaprophylaxe bei Hysterektomie	2006/15n1-GY	'N-OP/47637		· · · · · · · · · · · · · · · · · · ·	2008				
	9	Thromboseprophylaxe bei Hysterektomie	Thromboseprophylaxe bei Hysterektomie	2006/15n1-GY	'N-OP/50554							
Herzschrittmacher- Implantation	1	Leitlinienkonforme Indikationsetellung bei bradykarden Herzrhythmusstörungen	Leitlinienkonforme Indikations- stellung bei bradykarden Herz- rhythmusstörungen	2006/09n1-HS	M-IMPL/9962	(as	s part of	the mai				
	3	Leitlinienkonforme Systemwahl bei bradykarden Herzrhythmusstörungen	Leitlinienkonforme Systemwahl bei bradykarden Herzrhythmusstörungen	2006/09n1-HS	'M-IMPL/75973		ospitar c	quality re				
	5	Leitlinienkonforme Indikationsstellung und leitlinienkonforme	Leitlinienkonforme Indikations- stellung und leitlinienkonforme Systemwahl bei bradykarden	2006/09n1-H 76124	Leistungsbereich	LfdNr	Bezeichnung des Qualitätsindikators	Bezeichnung der Qualitätskennzal				
		Systemwahl bei bradykarden	Herzrhythmusstörungen		Knie-Totalendoprothesen- Erstimplantation	- 7	Postoperative Wund- infektion	Postoperative Wundinfektion				
	8	Herzrhythmusstörungen Perioperative Kompli- kationen	Perioperative Komplikationen: chirurgische Komplikationen	2006/09n1-H		10	Reinterventionen wegen Komplikation	Reinterventionen wegen Komplikation				
		Kattonen	Perioperative Komplikationen: Sondendislokation im Vorhof	2006/09n1-H	Koronarangiographie und Perkutane Koronarinter- vention (PCI)	1	Indikation zur Koronarangiographie Ischämiezeichen	Indikation zur Koronarangiogr Ischämiezeichen				
			Perioperative Komplikationen: Sondendislokation im Ventrikel	2006/09n1-H		3	Indikation zur PCI	Indikation zur PCI				
Hüft-Endoprothesen-	7	Endoprothesenluxation	Endoprothesenluxation	2006/17n2-H		4	Erreichen des wesentlichen Interventionsziels bei PCI	Erreichen des wesentlichen Interventionsziels bei PCI: All				
Erstimplantation	8	Postoperative Wund- infektion	Postoperative Wundinfektion	2006/17n2-H				mit Indikation akutes Koronar syndrom mit ST-Hebung bis 2				
	11	Reinterventionen wegen Komplikation	Reinterventionen wegen Komplikation	2006/17n2-H	oronarchirurgie, isoliert 5 Letalität		Letalität	Letaliät: Risikoadjustierte In-Hospital-Letalität nach logistischem KCH-SCORE				
Karotis-Rekonstruktion	1	Indikation bei asympto- matischer Karotisstenose	Indikation bei asymptomatischer Karotisstenose	2006/10n2-K	Mammachirurgie	2	Postoperatives Präparat- röntgen	Postoperatives Präparatröntge				
	2	Indikation bei sympto- matischer Karotisstenose	Indikation bei symptomatischer Karotisstenose	2006/10n2-K		3	Hormonrezeptoranalyse	Hormonrezeptoranalyse				
	7	Perioperative Schlaganfälle oder Tod risikoadjustiert	Perioperative Schlaganfälle oder Tod risikoadjustiert nach logistischem	2006/10n2-K		5	Angabe Sicherheitsabstand	Angabe Sicherheitsabstand: be Mastektomie				
		nach logistischem Karotis-Score I	Karotis-Score I. Risikoadjustierte Rate nach logistischem Karotis-Score I					Angabe Sicherheitsabstand: be brusterhaltender Therapie				
			1									

phase: public orting of 27 dicators datory from 2008 of the mandatory quality reports)

Indikation zur Koronarangiographie

Interventionsziels bei PCI: Alle PCI mit Indikation akutes Koronarsyndrom mit ST-Hebung bis 24 h Letaliät: Risikoadjustierte

Kennzahl ID

2006/17n5-KNIE-TEP/47390

2006/17n5-KNIE-TEP/45059

2006/21n3-KORO-PCI/43757

2006/21n3-KORO-PCI/69889

2006/21n3-KORO-PCI/69891

2006/HCH-KCH/66781

2006/18n1-MAMMA/46200

2006/18n1-MAMMA/46201

2006/18n1-MAMMA/68100

2006/18n1-MAMMA/68098

# An in-hospital approach: the HELIOS chain

- A standardized administrative data set is extracted from all hospital information systems weekly (containing coded diagnoses and procedures etc.) and automatically transferred to the company headquarter
- >700 medical outcome, volume and other indicators/ hospital
- 33 outcome indicators are defined as company goals: covering 30 important diseases and procedures (30% of all inpatient cases)

IELIOS Kliniken GmbH

- Results are distributed monthly to physicians (chairman) and CEOs (everybody can see everybody's results)
- Intra-chain competion alone already leads to improvement
- Living process: New indicators may be developed by specialty groups or centrally

× M	icroso	oft Excel - QS_2007_10b_neu.XLS										
3)	<u>D</u> atei	Bearbeiten Ansicht Einfügen Format Extras Daten Eenster ? PDF Create!								Frage	hier eingeben	8
		■ 🕒 🕘 🔍 🖤 🛝   X 🖻 🏝 • 🏈   ળ - № -   🔀 👷 Σ • ሷ↓ X↓   Δ	100% 🕞 🕢 📘									
Aria		- 10 - FKU ■言言語 翊 % 000 € ‰ 焱 掌 律			। 🗢 জা		Bh an Iwa	learbeitung zur	ückcenden t	Rearbailt ing beer	den	
Milia	224		= • <u>~</u> • <u>-</u> • <b>-</b>			0018		pearbeitunių zur	uusendenaant	learneirdi ig neer	uenne 🗧	
-	D2										121	+
1 2									•	•	•	
	А	В	С	D	E	F	G	Н	K	N	Q	T
						/ /	callo	Toto no.		A		
				1		HELIOST	odestalle HELIOS Pat	ant 100%	Berlinzen	endong) entineBu	•	
				1 1 -	3	5	°	amt	1eh	ende Benin Bu	· /	Schwerin
		Medizinische Unternehmensziele und Leistungskennzahlen bis 2007,		Quelle	HELIOS	ello	ELL SOS	Je	offin (B	othin	Erturt	charle
1		Konzernziele kumuliert 1.1. bis 31.10.2007		Q.	Y.	×.	4. 1.	P.	\$- -	\$* 	Ŷ	5
3		Erkrankungen des Herzens								l.		
3	1	Herzinfarkt	1				100	1		1	1	
5	11	Hauptdiagnose Herzinfarkt, Anteil Todesfälle, aufgetreten	unter Erwartungswert	St. BA	8.3%	333	4,013	4.3%	10.8%	8.4%	7.7%	11.7%
6		Hauptdiagnose Herzinfarkt, Anteil Todesfälle, erwartet	(Bund 10,7%)	St. BA	10.9%	(		11.7%	13.9%	9.2%	11.4%	10.8%
7		davon Herzinfarkt, Altersgruppe < 45, Anteil Todesfälle	unter 2,6%	St. BA	3.1%	5	162	0.0%	0.0%	0.0%	0.0%	0.0%
8		davon Herzinfarkt, Altersgruppe 45-64, Anteil Todesfälle	unter 4,3%	St. BA	3.3%	41	1,236	2.8%	0.0%	3.4%	0.0%	6.9%
9		davon Herzinfarkt, Altersgruppe 65-84, Anteil Todesfälle	unter 12,0%	St. BA	8.9%	195	2,181	3.5%	11.5%	9.9%	11.9%	11.4%
10	1.5	davon Herzinfarkt, Altersgruppe >=85, Anteil Todesfälle	unter 28,8%	St. BA	21.2%	92	434	12.5%	21.1%	33.3%	10.8%	32.4%
11 12	16	Hauptdiagnose Herzinfarkt, Direktaufnahmen ohne Verlegungen, Anteil Todesfälle	Beobachtungswert		11.1%	300	2,694	4.7%	22.2%	10.5%	7.8%	13.1%
13	1.0	Traupturagnose Herziniaikt, Direktaumannen onne venegungen, Anteir Touesiaile	Deubachtungsweit		11.170	000	2,004	4.7 70	22.270	10.5 %	7.070	13.170
14	2	Herzinsuffizienz										
15		Hauptdiagnose Herzinsuffizienz (Alter >19), Anteil Todesfälle, aufgetreten	unter Erwartungswert	St. BA	8.8%	581	6,615	8.7%	9.4%	4.7%	12.0%	8.7%
16		Hauptdiagnose Herzinsuffizienz (Alter >19), Anteil Todesfälle, erwartet	(Bund 11,4%)	St. BA	11.0%			10.8%	11.8%	9.7%	10.8%	10.4%
17	2.2	davon Herzinsuffizienz, Altersgruppe 20-44, Anteil Todesfälle	unter 4,1%	St. BA	1.5%	1	67	E 70/	0.0%	0.0%	0.0%	0.0%
18 19	2.3 5 л	davon Herzinsuffizienz, Altersgruppe 45-64, Anteil Trassine						5,7%	7.4%	1.3% 4.6%	10.0% 8.8%	1.0% 6.7%
20	2.4	davon Herzinsuffizienz, Altersgruppe 45-64, Anteil Torosti e davon Herzinsuffizienz, Altersgruppe 65-84, Anteil Torosti e davon Herzinsuffizienz, Altersgruppe >=85, Anteil Torosti e			<b>D</b> <sup>3,7%</sup>			19/5%	14.5%	4.0 %	25.0%	24.1%
21				7						10.070	20.070	
22	3	Behandlungsfälle mit Linksherzkatheter										
23	3.1	Summe der Fälle mit Linksherzkatheter mit Koronardiagnostik/-intervention	Mengeninformation		18,399		18,399	771	1	1,422	2,024	3,183
24	3.2	Fälle mit Linksherzkatheter BEI Herzinfarkt, ohne Herzoperation, Todesfälle, aufgetret		HELIOS	4.5%	119	2,619	3.2%		6.9%	3.6%	4.9%
25 26	50	Fälle mit Linksherzkatheter BEI Herzinfarkt, ohne Herzoperation, Todesfälle, erwarte Fälle mit Linksherzkatheter OHNE Herzinfarkt, ohne Herzoperation, Todesfälle	i unter 0,5%	<i>St. BA</i> HELIOS	9.1% 0.9%	134	15,501	11.2% 2.2%	0.0%	8.4% 1.4%	9.5% 1.4%	8.7% 0.6%
26 27	5.5	Falle mit Linksherzkatheter Offine Herzinlarkt, onne Herzoperation, Todestalle	unter 0,5%	HELIUS	0.9%	134	10,001	2.270	0.076	1.470	1.470	0.0%
28	4	Versorgung mit Schrittmacher oder implantierbarem Defibrillator										
29		Schrittmacherversorgung (Implantationen und Wechsel incl. Defibrillatoren)	Mengeninformation		2,901		2,901	201	36	247	336	305
30												
31		Schlaganfall (Stroke)										
32	5	Schlaganfall, alle Formen nach Altersgruppen										
33	5.1	Hauptdiagnose Schlaganfall, alle Formen, Anteil Todesfälle, aufgetreten	unter Erwartungswert		10.2%	467	4,582	6.6%	10.5%	12.8%	9.7%	8.3%
34 35	52	Hauptdiagnose Schlaganfall, alle Formen, Anteil Todesfälle, erwartet davon Schlaganfall, Altersgruppe 20-44, Anteil Todesfälle	( <i>Bund 11,4%)</i> unter 3,8%	<i>St. BA</i> St. BA	<u>11.4%</u> 2.4%	3	124	11.7% 0.0%	13.5% 0.0%	10.6% 12.5%	11.3% 0.0%	9.7% 0.0%
36	5.2 5.3	davon Schlaganfall, Altersgruppe 45-64, Anteil Todesfälle	unter 5,5%	St. BA	5.1%	43	845	1.9%	20.0%	8.0%	4.5%	3.1%
37	5.4	davon Schlaganfall, Altersgruppe 65-84, Anteil Todesfälle	unter 11,2%	St. BA	9.8%	278	2,842	5.4%	10.5%	14.0%	9.7%	10.1%
38		davon Schlaganfall, Altersgruppe >=85, Anteil Todesfälle	unter 21,0%	C+ D 4	10.5%	1.40	774	1C 70/	7 70/	14.00/	17.09/	10.59/
20									•			
4	► • H	/ 2007 Mindestmengen / Qualitätsübersicht ) Konzernziele 2007 / Rang Herzinsuf	fizienz / F	٨/\٨/	hΔ			Ini	<b>K T I I</b>	ohr	er (	
7eid	hnen v	📐 AutoFormen z 🔪 🔪 🖂 🖓 🦓 🖓 🖓 🖉 🖉 🖄 z 🦽 z 🗛 z 🚍 💳 💳							VI U			

Bereit

#### - methodology U.S. Department of Health & Human Services Agency for Healthcare Research and Quality Advancing Excellence in Health Care

- HELIOS indicators have been developed independently
- However international development necessarily shows parallels (medicine and goals are the same)
- AHRQ indicators **are less numerous and less differentiated**
- As far as there are AHRQ indicators (inpatient quality indicators IQI, patient safety indicators PSI),
  -> mostly to the same diseases as HELIOS indicators



# Comparison to US - results

Indicator	% change in in-hospital mortality				
	US	Germany			
	Medicare 1998-	HELIOS 2003-			
	2003 (5 yrs.)	2006 (3 yrs.)			
Pneumonia	-15.2%	-26.2%			
Myocardial infarction	-18.4%	-18.1%			
Stroke	-12.8%	-24.5%			
Cong. heart failure	-30.1%	-24.2%			
Aortic aneurysm	-7.0%	-13.3%			

Source: Thomas Mansky, Neue Methoden der Qualitätsmessung und des Qualitätsmanagements, in: Report Versorgungsforschung Band 1 – Monitoring der gesundheitlichen Versorgung in Deutschland. Köln, 2008, p. 149-170; the US data are based on Medicare Payment Advisory Commission (MEDPAC), Healthcare spending and the Medicare program. A data book, Washington DC 2005

# Switzerland

Schweizerische Eidgenossenschaft Confédération suisse Confederazione Svizzera Confederaziun svizra

 Switzerland – after a review of available systems – has decided to introduce HELIOS quality indicators as a Swiss national quality indicator system

- Swiss view: HELIOS compared favourably to AHRQ

- Currently we are in close cooperation for transferring our system to Switzerland (different coding systems etc.)
- Swiss data is already available at the ministry (BAG)
- Introduction is scheduled for this summer
  - Thus, Swiss results will be available for comparison with HELIOS


# Extending the scope: QSR (quality assurance with routine data)




- The largest German sickness fund (AOK) together with HELIOS has developed a new system to derive quality indicators from routine insurance claim data
  - due to availability of long term data and data from other sectors (outpatient, drugs ...), the approach is much wider
  - patient careers can be followed over years (up to lifetime)
  - indicators for long term outcome can be measured !
- Complications identifiable by specific readmissions
  - e.g. replacement of an endoprothesis due to any reason, any time after first implantation
  - readmission due to deep vein thrombosis
  - re-operation after colon resection due to abscess

QSR includes all hospitals with at least 4 AOK cases with a particular tracer indication

example: 90-day-<sup>25</sup> mortality after colorectal <sup>20</sup> cancer surgery in 1,026<sup>15</sup> hospitals (top with 95%<sup>10</sup> CI; bottom: lower limit<sup>5</sup> of 95% CI)




1026 Kliniken mit mindestens vier AOK-Patienten, sortiert nach 90-Tage-Sterblichkeit



1026 Kliniken mit mindestens vier AOK-Patienten, sortiert nach 90-Tage-Sterblichkeit

### QSR: cross-sectional benchmarking Example HELIOS Klinik Berlin Buch, heart failure

- 1,411 hospitals in Germany treat heart failure patients
- 90-day mortality ratio in Berlin-Buch in 2005 was 0.54, which is on the 8th percentile
- Such results have not yet been available on a routine basis in Germany




SMR = standardized mortality ratio; here SMRs of German hospitals, ordered by value (1 = German average)

### QSR: year-by-year vs. average Example HELIOS Klinik Berlin Buch, heart failure

- HELIOS quality management processes for heart diseases were set up in 2003
- 90-day heart failure mortality in Buch declined well below the adjusted German average
  - 2003 to 2005 is currently available from AOK


% 90-day mortality



Germany with 95% HELIOS confidence interval Berlin-Buch

### QSR: quality beyond discharge Example HELIOS Klinik Berlin Buch, heart failure


Risk adjusted heart failure mortality in Berlin-Buch is not only lower at discharge, but can still be observed after 1 year % mortality at discharge, after 30-days, 90-days, 1 year



### Germany with 95% HELIOS confidence interval Berlin-Buch



### Comparison of three approaches




### Disease Management Programs (since 2002)

- Compensate sickness funds for chronically ill better (make them attractive) = reduce faulty incentives to attract young & healthy
- Address quality problems by guidelines/ pathways
- Tackle trans-sectoral problems by "integrated" contracts for diabetes I/ II, asthma/ COPD, CHD, breast cancer
- = introduce Disease Management Programs meeting certain minimum criteria and compensate sickness funds for average expenditure of those enrolling

double incentive for sickness funds: potentially lower costs + extra compensation! By end of 2007: 3.8 mn enrolled (5.5% of SHI insured)


# DMP diabetes – first results


(age- but not severity-adjusted; *not* from official evaluation with post-intervention no control group design)



### **Evaluation of pharmaceuticals**

- Federal Joint Committee (FJC; founded 2004) has task to group drugs according to equal effectiveness (-> same reference price)
- may commission an evaluation through its Institute for Quality and Eficiency in Healthcare (IQWiG; founded 2004)
- 2007 reform extended FJC's mandate to set maximum reimbursement price for drugs of superior effectiveness; necessitates costeffectiveness evaluation through IQWiG





#### **Total Cost (/patient)**

http://www.iqwig.de/download/08-01-24\_ Relation the

# Conclusions

- Germany might have been slow with real quality innovations, but:
- Legal requirements provide framework for uniform approaches, providing benchmarking opportunities (*too little used, however*)
- Recently, IT improvements, better coding (DRGs!) and data availability have brought true innovative approches (*unfortunately usually not published internationally*)

Technische Universität Berlin



# This presentation and more material can be found on the following websites:

# http://mig.tu-berlin.de

# www.observatory.dk

